ResearchOncologyNuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer
Section snippets
Western blot analysis
We obtained 7 established human EOC cell lines with different sensitivities to cisplatin and p53 mutation status (Figure 1). Thirty-five micrograms of protein extracted from these 7 cell lines was loaded into each lane and fractionated by 10-12% sodium dodecyl sulfate polyacrylamide gel electrophoresis before being transferred to nitrocellulose membrane. The blots were then probed with antibodies against cyclin G1 (sc-7865; Santa Cruz Biotechnology, Santa Cruz, CA), p53 (Ab-12, DO-7;
Cyclin B1, cyclin G1, and p53 expression in EOC, LMP tumors, and NOE
Staining of cyclin B1 was found in the cytoplasm, nuclei, or both. Positive nuclear cyclin B1 staining was significantly higher in the LMP samples than in the NOE and EOC samples (P = .01; P < .001). No difference in nuclear cyclin B1 expression was observed between the NOE and EOC samples (Figure 2). When the serous LMP and EOC samples were analyzed, we found that the serous LMP samples still had significantly higher nuclear cyclin B1 expression than the NOE samples (P = .005). Higher nuclear
Comment
Altered regulation of cell cycle results in uncontrolled cell proliferation, which is the hallmark of cancer.4 Cell cycle progression is governed by a series of cyclins and cyclin-dependent kinases. Cyclin B1 and cyclin G1 are important cyclins in regulating G2/M transition, which is essential for mitosis and cell proliferation. Overexpression of cyclin B1 and cyclin G1 has been indicated in various human tumors, including breast, prostate, and lung cancers.9, 11, 13, 20, 21 However, there are
Acknowledgments
We thank Alyson Todd in the Department of Scientific Publications at M.D. Anderson Cancer Center for editing this manuscript.
References (36)
Clinical management potential tumours of low malignancy
Best Pract Res Clin Obstet Gynaecol
(2002)- et al.
Combinatorial control of cyclin B1 nuclear trafficking through phosphorylation at multiple sites
J Biol Chem
(2001) - et al.
The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity
Exp Cell Res
(1997) - et al.
Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53
Mol Immunol
(2002) - et al.
Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells
J Biol Chem
(1999) Origins and molecular pathology of ovarian cancer
Mod Pathol
(2005)- et al.
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Nat Rev Cancer
(2003) - et al.
Cell cycle control and cancer
Science
(1994) Cancer cell cycles
Science
(1996)- et al.
Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma
Cancer
(2006)
Cyclin B1 and CDK1: nuclear localization and upstream regulators
Prog Cell Cycle Res
Prognostic value of cyclin B1 protein expression in colorectal cancer
Am J Clin Pathol
Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses
Am J Pathol
Overexpression of cyclin B1 in human colorectal cancers
J Cancer Res Clin Oncol
Expression of cell cycle-regulated proteins in prostate cancer
Cancer Res
Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma
Virchows Arch
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication
Cancer Res
Regulation of cyclin G1 during murine hepatic regeneration following Dipin-induced DNA damage
Hepatology
Cited by (0)
Cite this article as: Zheng H, Hu W, Deavers MT, et al. Nuclear cyclin B1 is overexpressed in low-malignant-potential ovarian tumors but not in epithelial ovarian cancer. Am J Obstet Gynecol 2009;201:367.e1-6.